Table 2 Univariable analysis of clinical and molecular factors associated with CB vs. NCB, PFS and OS.
Clinical benefit (odds ratio for CB vs. NCB) | PFS, hazard ratio | OS, hazard ratio | |
|---|---|---|---|
Univariable (95% CI) [p-value] | Univariable (95% CI) [p-value] | Univariable (95% CI) [p-value] | |
Age | – | – | 1.02 (0.98 1.06) [0.42] |
Previous lines (≥1 vs. 0) | – | – | 0.89 (0.33 2.44) [0.83] |
Neut./lymph ratio Continuous variable | 0.77 (0.60 0.99) [0.04] | – | 1.12 (1.01 1.24) [0.03] |
Haemoglobin Continuous variable | 1.54 (1.10 2.17) [0.01] | 0.77 (0.65 0.91) [0.002] | 0.69 (0.54 0.88) [0.003] |
Platelet count Continuous variable | 0.997 (0.991 1.003) [0.32] | 1.003 (1.00 1.01) [0.07] | 1.003 (1.00 1.01) [0.16] |
Tract (bladder vs. UTUC) | 2.31 (0.65 8.24) [0.20] | 0.62 (0.32 1.21) [0.16] | 1.53 (0.52 4.53) [0.44] |
Gender | 0.82 (0.26 2.61) [0.73] | 1.24 (0.63 2.44) [0.53] | 1.13 (0.46 2.77) [0.80] |
ECOG PS (≥1 vs. 0) | 0.14 (0.05 0.46) [0.001] | 3.00 (1.48 6.06) [0.002] | 6.19 (1.93 19.86) [0.002] |
Visceral/LN Mets. | 0.03 (0.01 0.17) [<0.001] | 6.91 (2.44 19.57) [<0.001] | 14.49 (1.91 110.07) [0.010] |
Genomic variable | |||
SNV count/TMB Continuous variable | 1.36 (1.16 1.60) [<0.001] | 0.88 (0.82 0.95) [ < 0.001] | 0.94 (0.86 1.02) [0.14] |
CNV count Continuous variable | 0.40 (0.20 0.81) [0.01] | 1.42 (1.11 1.81) [0.01] | 1.12 (0.78 1.63) [0.54] |
C>T CpG signature mutations Continuous variable | – | 0.89 (0.78 1.02) [0.11] | 0.96 (0.81 1.15) [0.69] |
ERCC2 signature mutations Continuous variable | – | – | 0.95 (0.77 1.16) [0.60] |
APOBEC signature mutations Continuous variable | 1.31 (1.09 1.58) [0.004] | – | 0.91 (0.81 1.03) [0.15] |
CDKN2B homozygous deletion | 0.08 (0.01 0.69) [0.02] | 3.84 (1.93 7.61) [<0.001] | 4.12 (1.64 10.34) [0.003] |
DDR deleterious alterations (Yes vs. No) | 3.07 (0.98 9.59) [0.14] | – | 0.61 (0.23, 1.62) [0.55] |
